Abstract
In recent years, significant progresses have been achieved in clinical oncology due to a plethora of new chemotherapeutic drugs and agents for targeted therapy. However, clinical response and overall survival rates have not improved significantly for a large number of different tumors. This may at least in part be due to the enormous genetic heterogeneity among tumors, even within a tumor entity. Moreover, besides individual somatic mutations or combinations of these in malignant tumors, the genetic background of each individual cancer patient appears to have a major impact on treatment response and overall survival. Current DNA microarray technology allows the simultaneous gene expression analysis of all known genes, and large-scale gene expression studies have provided new molecular classifications for a series of different tumors. Evidence has also been provided that gene expression signatures of malignant tumors may predict treatment response to classical chemotherapeutic or targeted anticancer drugs. The presented report summarizes the current knowledge about the role of gene expression signatures as putative guides for treatment decisions, with the future prospect of individualized treatment approaches for cancer patients.
Keywords: Genomics, cancer, chemotherapeutics, personalized treatment
Current Drug Discovery Technologies
Title: Genomic Signatures for Individualized Treatment of Malignant Tumors
Volume: 5 Issue: 1
Author(s): Manfred Kunz
Affiliation:
Keywords: Genomics, cancer, chemotherapeutics, personalized treatment
Abstract: In recent years, significant progresses have been achieved in clinical oncology due to a plethora of new chemotherapeutic drugs and agents for targeted therapy. However, clinical response and overall survival rates have not improved significantly for a large number of different tumors. This may at least in part be due to the enormous genetic heterogeneity among tumors, even within a tumor entity. Moreover, besides individual somatic mutations or combinations of these in malignant tumors, the genetic background of each individual cancer patient appears to have a major impact on treatment response and overall survival. Current DNA microarray technology allows the simultaneous gene expression analysis of all known genes, and large-scale gene expression studies have provided new molecular classifications for a series of different tumors. Evidence has also been provided that gene expression signatures of malignant tumors may predict treatment response to classical chemotherapeutic or targeted anticancer drugs. The presented report summarizes the current knowledge about the role of gene expression signatures as putative guides for treatment decisions, with the future prospect of individualized treatment approaches for cancer patients.
Export Options
About this article
Cite this article as:
Kunz Manfred, Genomic Signatures for Individualized Treatment of Malignant Tumors, Current Drug Discovery Technologies 2008; 5 (1) . https://dx.doi.org/10.2174/157016308783769423
DOI https://dx.doi.org/10.2174/157016308783769423 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Decoding the Knots of Initiation of Oncogenic Epithelial-Mesenchymal Transition in Tumor Progression
Current Cancer Drug Targets Lactate Transporters and pH Regulation: Potential Therapeutic Targets in Glioblastomas
Current Cancer Drug Targets ABC Transporters and Drug Resistance in Patients with Epilepsy
Current Pharmaceutical Design Modulation of intracellular pH in human ovarian cancer.
Current Molecular Medicine Liposomal Doxorubicin Delivery Systems: Effects of Formulation and Processing Parameters on Drug Loading and Release Behavior
Current Drug Delivery Rab GTPases, Membrane Trafficking and Diseases
Current Drug Targets Histopathological Determinants of Tumor Resistance: A Special Look to the Immunohistochemical Expression of Carbonic Anhydrase IX in Human Cancers
Current Medicinal Chemistry Targeting Epigenome As An Innovative Pharmacological Strategy For Castration-resistant Prostate Cancer
Clinical Cancer Drugs GH-Inhibitory Activity of Novel Somatostatin Agonists: Potential Applications in Acromegaly
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Melanoma Differentiation Associated Gene-7 (mda-7)/ Interleukin-24 (IL-24), mda-7/IL-24: Current Perspectives on a Unique Member of the IL-10 Family of Cytokines
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Current Strategy for Cisplatin Delivery
Current Cancer Drug Targets Surface Markers of Cancer Stem Cells in Solid Tumors
Current Stem Cell Research & Therapy Human Leukemia and Lymphoma Cell Lines as Models and Resources
Current Medicinal Chemistry The Role of Hypoxia in Endometrial Cancer
Current Pharmaceutical Biotechnology Physicochemical Properties that Determine Cellular Transport of Nanocarriers In Vitro and In Vivo
Current Organic Chemistry Peroxisome Proliferator-Activated Receptors: Role of Isoform Gamma in the Antineoplastic Effect of Iodine in Mammary Cancer
Current Cancer Drug Targets Expression of Specificity Protein Transcription Factors in Pancreatic Cancer and their Association in Prognosis and Therapy
Current Medicinal Chemistry Iron Chelating Strategies in Systemic Metal Overload, Neurodegeneration and Cancer
Current Medicinal Chemistry Preface
Anti-Cancer Agents in Medicinal Chemistry Validated RP-HPLC Method for the Simultaneous Analysis of Gemcitabine and LY-364947 in Liposomal Formulations
Current Drug Targets